On May 19, 2017, Fujifilm launched the hybrid instant camera *instax SQUARE SQ10* with the new square format film *instax SQUARE Film*, as a new lineup for instax series that allows users to enjoy output photos on the spot. The *instax SQUARE SQ10* is the first hybrid camera within its range equipped with a digital image sensor and digital image processing technology, enabling greatly improved photographic image quality and image editing/processing before printing. While it takes over the strong points of instax series of being enabled to users to get the photos on the spot, texture of unique printings and simple operability, it meets users’ needs of taking photos under difficult scenes such as in low-light conditions and close-up shots, fastidiousness of color and expression by equipping digital image technology.

Fujifilm is adding three new models to its UA Series of 4K broadcast lenses. The compact and lightweight portable zoom lenses, *FUJINON UA 18x5.5* and *FUJINON UA 14x4.5*, has launched in late April, 2017, while the 27x studio zoom lens, *FUJINON UA 27x6.5*, is scheduled for release in late June, 2017.

The *FUJINON UA 18x5.5* covers the focal lengths of 5.5mm - 100mm to capture a wide range of scenes. The *FUJINON UA 14x4.5* is an ultra wide angle lens covering the focal lengths of 4.5mm - 63mm, putting you right in the midst of action. The *FUJINON UA 27x6.5* is a 27x zoom lens that covers the focal lengths of 6.5mm - 180mm for versatility.

The addition of the latest three models expands Fujifilm’s 4K broadcast lens lineup to 7 models in total, catering to the growing global needs for 4K video production.

In June, 2017, Fujifilm is adding two fixed single lenses, which realize description of overwhelming resolution and depth for interchangeable lenses of GFX series, medium format mirrorless camera, adopting a large-size sensor. The *FUJINON GF110mmF2 R LM WR Lens* is a medium telephoto lens for portraits. With a focal length equivalent to 87mm in the 35mm format, it achieves a brightness of F2.0 when used wide open to deliver beautiful bokeh. The *FUJINON GF23mmF4 R LM WR Lens* has a focal length equivalent to 18mm in the 35mm format and is perfectly suited for landscape and architectural applications.
Fujifilm has launched the Fine Chemical Division as of April 1, 2017 to expand its business of high-function chemicals and laboratory chemicals.

Fujifilm formally completed the offer on April 3, 2017 in which Wako Pure Chemical Industries, Ltd. would become a consolidated subsidiary as of April 21, 2017 in an effort to strongly promote the company's existing speciality chemical and laboratory chemical business. Fujifilm established a business structure to create synergy with Wako Pure Chemical*.

To achieve further business expansion, Fujifilm will also market its library of two hundred thousand varieties of chemical compounds through Wako Pure Chemical's refined distribution routes across Japan, and make use of our overseas network to market Wako Pure Chemical's speciality chemicals and laboratory chemicals. Business growth will be accelerated through combining the two companies' advanced chemical synthesis technology, to develop and provide new high-function chemicals and laboratory chemicals.

* Of Wako Pure Chemical's "laboratory chemicals," "clinical diagnostic drugs" and "specialty chemicals," the Fine Chemical Division deals with "laboratory chemicals" and "specialty chemicals" (excluding some products such as cell culture medium and semiconductor materials).

Fujifilm will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand its contract development and manufacturing operations for biopharmaceuticals**, the business of its Bio CDMO*** Division.

In the USA, at FUJIFILM Diosynth Biotechnologies Texas, LLC, a JPY10 billion ($93m) cGMP production facility has been completed. This facility was built in part with funding from BARDA (Biomedical Advanced Research and Development Authority), an office of the U.S. Department of Health and Human Services, and Fujifilm plans to invest an additional JPY3 billion ($28m) to outfit the facility with mammalian cell culture bioreactors. This facility will start operation at the beginning of 2018.

In addition, a JPY1 billion ($9m) investment will be made to expand the Process Development capabilities at FUJIFILM Diosynth Biotechnologies UK Limited near to its Billingham, UK site. This facility is scheduled to be operational in summer of 2017.

** Pharmaceutical products manufactured through biological process, which usually functions differently from small molecule drugs. It includes various products such as vaccines, insulins, growth hormones, antibodies etc.  
*** CDMO stands for Contract Development & Manufacturing Organization. CDMO provides clients such as pharmaceutical and biotechnology companies with a wide range of services from cell line development in the early stage of pharmaceutical development to process development, stability testing, investigational drug development / manufacturing and commercial drug manufacturing.